Jazz Pharmaceuticals Support Services

Patient Support Services Guide 2019


Patient Assistance
888-837-4397 | 855-589-9367

Jazz Pharmaceuticals, through its JumpStart Program, offers patients support for its hematology/oncology drugs—Defitelio (defibrotide sodium), Erwinaze (asparaginase Erwinia chrysanthemi), and Vyxeos (dauno­rubicin and cytarabine) liposome (Table).

Defitelio is indicated for the treatment of patients with hepatic VOD (veno-occlusive disease) associated with renal or pulmonary dysfunction after hematopoietic stem-cell transplantation.

Erwinaze is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to Escherichia coli–derived asparaginase.

Vyxeos is indicated for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) and for AML with myelodysplasia-related changes (AML-MRC).

The JumpStart Program

The JumpStart Program provides patients who are prescribed Defitelio, Erwinaze, or Vyxeos access to these medications through several financial assistance options. A patient assistance program is also offered for these 3 medications.

Eligibility

To be eligible for the JumpStart Program, a patient must:

  • Be a legal US resident
  • Have a valid prescription for Defitelio or for Erwinaze for indicated uses
  • Receive treatment on an outpatient basis
  • Have no insurance coverage or no coverage for Defitelio, Erwinaze, or Vyxeos.

In addition, the patient must provide proof of income, including ≥1 of these documents—a copy of a current federal income tax return, W-2 forms, yearly benefit statement (Social Security form 1099), pay stubs, and bank statements for 3 months for all earners in the household. For more information about eligibility and assistance, please contact JumpStart specialists at 888-837-4397 for Defitelio or Erwinaze, and at 855-589-9367 for Vyxeos.

Application & Enrollment

Completed JumpStart forms may be submitted by:

Table Jazz Pharmaceuticals Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Defitelio (defibrotide sodium)
Indication
Patients with hepatic VOD (veno-occlusive disease) associated with renal or pulmonary dysfunction after hematopoietic stem-cell transplantation
Patient support program

Drug
Erwinaze (asparaginase Erwinia chrysanthemi)
Indication
Acute lymphoblastic leukemia for patients with hypersensitivity to Escherichia coli–derived asparaginase
Patient support program

Drug
Vyxeos (daunorubicin and cytarabine) liposome
Indication
Adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Patient support program